Cellular Biomedicine Group Announces FDA Clearance of Investigational New Drug Application for Novel TIL Therapy C-TIL051
proceed with Phase 1 clinical development of its novel Tumor Infiltrating Lymphocyte (TIL) product C-TIL051 for late-stage Non-Small Cell Lung Cancer (NSCLC) patients that are relapsed or refractory to anti-PD1 therapy. C-TIL051 is an autologous adoptive cell therapy comprised of a patient's ex vivo expanded lymphocytes using CBMG's proprietary manufacturing process.